^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VMD-928

    i
    Other names: VMD-928
    Associations

    News

    Trials
    Company:
    Vm Oncology
    Drug class:
    TrkA receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=74, Recruiting, VM Oncology, LLC | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    VMD-928
    10ms
    Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=74, Recruiting, VM Oncology, LLC | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    NTRK1 fusion • NTRK1 mutation • NTRK expression
    |
    VMD-928
    over1year
    Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=74, Recruiting, VM Oncology, LLC | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    NTRK1 fusion • NTRK1 mutation • NTRK expression
    |
    VMD-928
    over2years
    Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=74, Recruiting, VM Oncology, LLC | N=54 --> 74 | Trial completion date: Dec 2022 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Dec 2023
    Enrollment change • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    NTRK1 fusion • NTRK1 mutation • NTRK expression
    |
    VMD-928
    almost4years
    Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=54, Recruiting, VM Oncology, LLC | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    NTRK1 fusion • NTRK1 mutation • NTRK expression
    |
    VMD-928
    almost5years
    Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma (clinicaltrials.gov)
    P1, N=54, Recruiting, VM Oncology, LLC | Trial completion date: May 2020 --> Dec 2021 | Trial primary completion date: Nov 2019 --> Jun 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    NTRK1 fusion • NTRK1 mutation • NTRK expression
    |
    VMD-928